Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The page now highlights that Tagrisso combined with chemotherapy has shown a median overall survival of nearly four years in a significant clinical trial for EGFR-mutated advanced lung cancer, while the previous mention of Imfinzi's approval for bladder cancer has been removed.
    Difference
    11%
    Check dated 2025-09-07T17:26:40.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The page now highlights the positive results of the BaxHTN Phase III trial for Baxdrostat, indicating its effectiveness in reducing systolic blood pressure for patients with hard-to-control hypertension. The previous mention of Datroway's approval for a specific cancer treatment has been removed.
    Difference
    10%
    Check dated 2025-08-31T12:13:33.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    48 days ago
    Change Detected
    Summary
    The webpage now includes information about Imfinzi receiving Priority Review and Breakthrough Therapy Designation in the US for early-stage gastric and gastroesophageal junction cancers, along with updates for Q2 2025 results. Several previous updates regarding COVID-19 and collaborations have been removed.
    Difference
    74%
    Check dated 2025-08-01T18:57:50.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The web page has added significant updates regarding new drug approvals and clinical trial results, including a positive opinion for Trixeo Aerosphere and AstraZeneca's substantial investment in the U.S. for medicine manufacturing. However, several important clinical trial results have been removed, which may affect the comprehensiveness of the information provided.
    Difference
    80%
    Check dated 2025-07-25T14:00:32.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The webpage has been updated with new information regarding the CARES Phase III clinical programme for anselamimab and the successful results of the BaxHTN Phase III trial for Baxdrostat, while previous updates about Imfinzi and AstraZeneca's achievements have been removed.
    Difference
    77%
    Check dated 2025-07-18T10:59:03.000Z thumbnail image
  8. Check
    70 days ago
    Change Detected
    Summary
    The web page now includes information about Imfinzi being approved in the EU as the first and only perioperative immunotherapy for muscle-invasive bladder cancer. The previous mention of the acquisition of EsoBiotec has been removed.
    Difference
    5%
    Check dated 2025-07-11T07:07:30.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.